
Altimmune (ALT) Stock Forecast & Price Target
Altimmune (ALT) Analyst Ratings
Bulls say
Altimmune is a late clinical-stage biopharmaceutical company with a strong candidate in pemvidutide targeting serious liver diseases including MASH, AUD, and ALD, with additional indications in the pipeline. With Phase 3 PERFORMA trial initiation expected in 2026 and Ph2 RECLAIM and RESTORE trials providing de-risking catalysts, Altimmune's differentiated clinical profile and 75% probability of success for pemvidutide in MASH could lead to peak sales of $3B worldwide. Additionally, the company's strong financial position with pro-forma cash of $340M and strategic partnerships, along with its novel AI-assisted decision-support tool, could reduce inter-reader variability and expedite timelines for drug development. While there are clinical and financial risks associated with NASH development, Altimmune remains well-positioned in the third wave of candidates seeking FDA and EMEA approval in the 2026+ timeframe.
Bears say
Altimmune is a clinical-stage biopharmaceutical company with promising drug candidate pemvidutide targeting multiple serious liver diseases and expanding into AUD and ALD indications, but its early development stage, crowded competitive landscape, and uncertainty about the commercial market for these indications present major risks for the company. The recent financing deals and strong balance sheet are positive indicators, but the lack of proof-of-concept data and future capital requirements also need to be closely monitored.
This aggregate rating is based on analysts' research of Altimmune and is not a guaranteed prediction by Public.com or investment advice.
Altimmune (ALT) Analyst Forecast & Price Prediction
Start investing in Altimmune (ALT)
Order type
Buy in
Order amount
Est. shares
0 shares